19.01.2015 • News • People • Biesterfeld • Birger Kuck

Thomas Arnold to Become CEO of Biesterfeld

Thomas Arnold will become CEO of Biesterfeld with effect of April 1, 2015.
Thomas Arnold will become CEO of Biesterfeld with effect of April 1, 2015.

The Supervisory Board of Biesterfeld has appointed Thomas Arnold (54) as CEO with effect of April 1, 2015. Arnold, currently member of the board of Biesterfeld and Managing Director of Biesterfeld Spezialchemie, takes over from Birger Kuck, who will retire after eleven years as CEO and a total of 35 years with the company on March 31, 2015.

Arnold joined Biesterfeld in May 2013 and was appointed to the board of Biesterfeld in July 2014. Prior to this he held management positions in various renowned, international companies in the trade.

 

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.